Alzheimer’s disease is the fourth biggest killer in developed countries. Amyloid precursor protein (APP) plays a central role in the development of the disease, through the generation of a peptide called Aβ by proteolysis of the precursor protein. APP can function as a metalloprotein and modulate copper transport via its extracellular copper binding domain (CuBD). Copper binding to this domain has been shown to reduce Aβ levels and hence a molecular understanding of the interaction between metal and protein could lead to the development of novel therapeutics to treat the disease. We have recently determined the three-dimensional structures of apo and copper bound forms of CuBD. The structures provide a mechanism by which CuBD could readily transfer copper ions to other proteins. Importantly, the lack of significant conformational changes to CuBD on copper binding suggests a model in which copper binding affects the dimerisation state of APP leading to reduction in Aβ production. We thus predict that disruption of APP dimers may be a novel therapeutic approach to treat Alzheimer’s disease.
Copper binding to the Alzheimer’s disease amyloid precursor protein
G.K.-W. Kong,Luke A Miles,Gabriela A. N. Crespi,C. Morton,Hooi Ng,K. Barnham,W. McKinstry,R. Cappai,M. Parker
Published 2007 in European Biophysics Journal
ABSTRACT
PUBLICATION RECORD
- Publication year
2007
- Venue
European Biophysics Journal
- Publication date
2007-11-21
- Fields of study
Medicine, Chemistry
- Identifiers
- External record
- Source metadata
Semantic Scholar, PubMed
CITATION MAP
EXTRACTION MAP
CLAIMS
- No claims are published for this paper.
CONCEPTS
- No concepts are published for this paper.
REFERENCES
Showing 1-67 of 67 references · Page 1 of 1
CITED BY
Showing 1-77 of 77 citing papers · Page 1 of 1